Technology | March 10, 2010

Statin-Based Drug Lowers Bad Cholesterol

An FDA-approved, cholesterol-lowering medication has been proven to significantly reduce the risk of heart attack, stroke, certain kinds of heart surgeries and chest pain.

Over 29 million people in the United States have been prescribed Lipitor, manufactured by Pfizer. It is one of the most widely studied medicines in the world — with more than 17 years of research, and over 400 ongoing or completed clinical studies encompassing over 80,000 patients.

In clinical studies, Lipitor lowered bad cholesterol significantly more than generic Zocor (simvastatin). Lipitor is a statin that lower cholesterol in your body by blocking an enzyme in the liver. Bodies uses this enzyme to make cholesterol. When less cholesterol is made, the liver uses more of it from the blood, which results in lower levels of cholesterol in the blood.

Along with diet and exercise, Lipitor is proven to:

• Lower LDL ("bad" cholesterol) by 39 to 60 percent
• Lower triglycerides (a type of fat found in the blood) by 19 to 37 percent
• Raise HDL ("good" cholesterol) by 5 percent to 9 percent

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init